Making cancer cells visible during surgery
Integro Theranostics is a clinical stage company developing fluorescent imaging agents and associated medical devices that enable surgeons to readily see and remove cancerous tissue. This accurate, real-time visualization of cancer tissue facilitates a more complete removal of cancer during surgery.
Optimizing Cancer Clinical Trials with Real Time AI Powered Solutions
Integro Theranostics is a clinical stage company developing an AI powered approach to provide actionable insights and enhanced decision making to optimize the surgical removal of cancer. In its partnership with OmniScience, clinical data scientists have created an AI-driven process that enables deep tissue analysis at both the gross and microscopic levels. This enables the following:
Identify patterns and trends through algorithms that enhance the detection of cancer with greater accuracy during surgery
Deliver data-driven clinical decision support by unifying imaging data to optimize cancer trial insights with traceable pathways
Streamline data and analysis processes to unlock new efficiencies and simplify workflows
Enable intraoperative pathology assessment through computer vision that helps identify cancer.
We use fluorescence to improve patient outcomes.
Complete removal of cancerous tumor tissue and lymph nodes is the hallmark of a successful surgery. However, surgeons have limited insight into the success of surgery while in the operating room, resulting in increased risk of cancer recurrence and a high rate of repeat surgeries.
With Integro’s fluorescent imaging agent, LS301, surgeons can easily see the amount and location of cancer cells and differentiate between healthy and cancerous tissue during surgery.
Meet Scientific Visionary Dr. Samuel Achilefu
The inventor of Integro’s revolutionary technologies is a pioneering expert in the design and use of fluorescent molecules to improve cancer imaging.
Committed to Addressing Health Disparities
Our product development priorities are informed by our commitment to improving disparities in cancer treatment and patient outcomes. Inadequate health insurance, poor access to high-quality detection and treatment, and lack of diversity in clinical trials are just some of the myriad of factors that contribute to cancer health disparities. Integro is committed to developing products that are accessible to all patients and in establishing partnerships to pursue cancer health equity.
-
Black people are more likely to die from most cancers than any other racial or ethnic group. Giaquinto et al. reported that Black women are twice as likely to die from endometrial cancer and 41% more likely to die from breast cancer compared to white women in the US despite similar incidence rates. LS301 could provide an effective strategy for detecting and removing even the most aggressive type of breast cancer, triple negative breast cancer, which is twice as likely to be diagnosed in Black women.
-
Many minority populations are significantly underrepresented in cancer clinical trials, with these racial and ethnic groups also experiencing disparities in cancer care and outcomes. A study evaluating racial and ethnic representation in the 230 clinical trials that supported FDA oncology drug approvals from 2008-2018 found that only 3.1% of clinical trial participants were Black (Blacks represent 13.5% of the US population) and only 6.1% were Hispanic (Hispanics represent 18.5% of the US population). Integro Theranostics is committed to forging partnerships that will help to engage more minority participants in LS301 clinical trials.